Sleep apnea is an important comorbidity in patients with chronic kidney disease (CKD). Although the increased prevalence of sleep apnea in patients with CKD is well established, few studies have examined the full spectrum of kidney function. We sought to determine the prevalence of sleep apnea and associated nocturnal hypoxia in patients with CKD. We hypothesized that the prevalence of sleep apnea would increase progressively as kidney function declines. 45 patients were recruited from outpatient nephrology clinics, nephrology department, and hemodialysis units. All patients completed an overnight inpatient polysomnograhy test to determine the prevalence of sleep apnea (AHI ≥ 5 events /h) and nocturnal hypoxia (oxygen saturation (SaO2) below 90% for ≥12% of the nocturnal monitoring time). Patients were stratified according to their estimated glomerular filtration rate (eGFR) at the time of the study visit into three groups as follows: CKD stage 2 (eGFR 60 to 89 mL/min/1.73 m2) (control group), CKD stages 3 and 4 (eGFR 15 to 59 mL/min/1.73 m2), and CKD stage 5 (eGFR <15 mL/min/1.73 m2). eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Out of the 45 patients included in our study with the full spectrum of kidney function, ranging from those with eGFR 60 to 89 ml/min./1.73m2 to patients with eGFR <15 ml/min./1.73m2, 15 (33.3%) had sleep apnea (Mean AHI; 8.71±5.86). Our study found that prevalence of sleep apnea increased as kidney function declined (Group (I), 20%; Group (II), 36.4%; Group (III), 37.5%). Furthermore, severity of sleep apnea increased as kidney function declined (Group (I), mean AHI: 5.75±0.35; Group (II), mean AHI: 6±1.38; Group (III), mean AHI: 10.6±7.04). We also found that prevalence of nocturnal hypoxia which is characteristically associated with sleep apnea was greater among groups (II) and (III) (27.3% and 16.7%, respectively) than in group (I) (10%). Severity of nocturnal hypoxia increased as kidney function declined (Group (I), 13%; Group (II), 13.6±1.22%; Group (III), 16.75±3.30%). Overall, 8 out of the 45 studied CKD patients (17.8%) had nocturnal hypoxia (Mean SaO2 below 90% for ≥12% of the nocturnal monitoring time; 15.1±2.87%). Our study revealed that as kidney function declined, Apnea/Hypopnea (AHI) indices increased, oxygen desaturation indices increased, minimal peripheral capillary oxygen saturation values decreased, peripheral capillary oxygen saturation time <90% increased, and snore indices increased. Also, respiratory distress index (RDI) was higher among groups (II) and (III) than in group (I). However, only differences between groups as regards respiratory distress events, respiratory distress indices, snore events, and snore indices were statistically significant. These results show that as kidney function declines, several respiratory parameters deteriorate during sleep. In addition, wake events and indices, and sleep stage 1 (%) increased as kidney function deteriorated. Sleep efficiency (%) was highest among group (I) patients and lower among groups (II) and (III), Light sleep (%) was lowest among group (I) patients and higher among groups (II) and (III), and deep sleep (%) was highest among group (I) patients and lower among groups (II) and (III). It is clear from the above results that as kidney function declines, sleep efficiency deteriorates, wake indices increase, light sleep (%) increases, and deep sleep (%) decreases. We concluded that prevalence and severity of sleep apnea in patients with CKD increase as kidney function declines. Almost 18% of patients with CKD experience nocturnal hypoxia, which may contribute to loss of kidney function.
INTRODUCTION
Sleep apnea (SA) is defined as an intermittent interruption of airflow at the level of nose and mouth during sleep. Episodes of apnea are considered important if they persist for longer than 10 seconds, but in some cases they may last as long as 2 minutes. The SA syndrome is the clinical consequence of frequent episodes of apnea during sleep. Usually patients with the full-blown syndrome have at least ten episodes of apnea per hour. The syndrome is probably the most important cause of daytime somnolence 1 
.
Sleep apnea (SA) may be obstructive or central. Obstructive sleep apnea (OSA) is characterized by a complete or partial obstruction of the upper airways, due to relaxation of the musculature combined with mechanical factors, such as tissue adiposity and cranio-facial structure, which causes apnoea or hypopnoea during sleep 2 . Central apnoea (CSA) on the other hand is due to a cessation of voluntary respiratory drive from the central respiratory centre in the hypothalamus 3 .
The airway remains open during CSAs/hypopnoeas. These apnoeas and hypopnoeas are often accompanied by arterial hypoxia, a rise in carbon dioxide and increased sympathomimetic discharge. The net result is a repetitive interruption of nocturnal sleep, increased heart rate, reversal of the diurnal variation of blood pressure and daytime fatigue and hypersomnolence. There are complex relationships between SA and increased cardiovascular risks. Patients are at increased risk of developing essential hypertension, heart disease and mortality due to cardiovascular causes 4 . There is an increased risk of ischaemic stroke in patients with untreated SA and direct consequences on recent memory retention, reduced neuro-psychological function, depression and deteriorating quality of life 5 . The coexistence of sleep apnea in patients with Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) is likely to have clinical relevance. In addition to impairment of sleep quality and daytime function 6 , sleep apnea increases the risk of hypertension 7 , atherosclerosis, and vascular disease 8 . Vascular disorders are common to both patients with CKD and patients with ESRD, and their prevalence may be further increased by unrecognized sleep apnea 9 . Further, sleep apnea is characteristically associated with nocturnal hypoxia, which is the main biologic mechanism through which these vascular complications develop 9 . It is also possible that sleep apnea accelerates the deterioration of kidney function in patients with CKD either indirectly by increasing systemic BP, inflammatory cytokines, and sympathetic nervous system activity 10 (all of which have been proposed to reduce kidney function) or directly through the effect of hypoxia on the kidney 11 . There are several reasons why the increased risk of OSA is significantly associated with decreased glomerular filtration rate (GFR) among these patients. First, the upper airway dimensions in patients with renal failure are prone to narrowing. Beecroft et al. reported that the pharyngeal cross-sectional area measured by pharyngometry in end-stage renal disease patients was 12% less than that in the normal renal function control group matched for body mass index (BMI) 12 . Such pharyngeal narrowing was considered to occur because of upper airway edema due to systemic fluid overload and upper airway dilator muscle dysfunction due to neuropathy or myopathy associated with chronic uremia 12 . Second, ventilation control is known to be instable in CKD patients. Because chemoreflex responsiveness has been reported to be augmented in patients with end-stage renal disease, possibly because of the accumulation of uremic molecules or metabolic acidosis, this destabilized respiratory control-as explained by a high "loop gain" theory-can contribute to the pathogenesis of OSA 13 . Although these two mechanisms have been established in hemodialysis patients, it is possible that they are also applicable to the nondialysis CKD population. Nocturnal hypoxia has been demonstrated to be independently associated with an increased risk for accelerated loss of kidney function 14 . The chronic hypoxia hypothesis suggests that chronic ischemic damage in the tubulointerstitium of the kidney is the final common pathway for the development of ESRD 11 . If such a process is already under way in patients with CKD, it is possible that ongoing nocturnal hypoxia will amplify the effect and accelerate the decline in kidney function. If so, identification and treatment of nocturnal hypoxia may provide a potential disease-modifying intervention that could delay or halt the progression of CKD to ESRD.
Aim of work
The aim of this work is to study sleep-disordered breathing in patients with chronic kidney disease.
SUBJECTS AND METHODS
Among adult patients attending outpatient nephrology clinics, hemodialysis units, and those hospitalized in nephrology departments at Cairo university hospitals, 45 cases were invited to participate in this study. Patients were stratified according to their estimated glomerular filtration rate (eGFR) at the time of the study visit into three groups as follows: CKD stage 2 (eGFR 60 to 89 mL/min/1.73 m2) (control group), CKD stages 3 and 4 (eGFR 15 to 59 mL/min/1.73 m2), and CKD stage 5 (eGFR <15 mL/min/1.73 m2). eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 15 . Mixed apnea: Absence of respiratory effort at the beginning of the event followed by increasing respiratory effort during the second half 17 . Hypopnea Reduction in airflow ≥ 50% from baseline, recorded by nasal pressure cannulas or alternatively by induction plethysmography or oronasal thermistors. Duration ≥ 10 sec. Reduction in airflow at least 90% of the event. Reduction in saturation ≥ 4% from baseline prior to the event. A desaturation is scored when these two parameters are met Chi-square (X 2 ) test of significance was used in order to compare proportions between two qualitative parameters. Probability (P-value) P-value <0.05 was considered significant. P-value 0.01 was considered as highly significant. P-value >0.05 was considered insignificant. It is evident from the above results that severity of nocturnal hypoxia increased as eGFR declined. Also, prevalence of nocturnal hypoxia among groups (II) and (III) were greater than group (I).
RESULTS

Using AHI for Diagnosis of Sleep Apnea
DISCUSSION
A total of 45 patients (eGFR 60 to 89 ml/min./1.73m2, n 10; eGFR 15 to 59 ml/min./1.73m2, n 11; eGFR <15 ml/min./1.73m2, n 24) were included in this study with matched mean ages across the three groups (Group (I), 45.30±9.68; Group (II), 45.27±15.82; Group (III), 45.21±16.66). No statistically significant differences between groups were found as regards age and sex (Table 9) . In the present study we examined patients with the full spectrum of kidney function, ranging from those with eGFR 60 to 89 ml/min./1.73m2 to patients with eGFR <15 ml/min./1.73m2. Second, all patients were recruited from nephrology clinics and hemodialysis units, including those with minimally impaired kidney function (eGFR >60), which we believe is the most appropriate control group for this study. Third, patients were not excluded by age, sex, comorbidities, or medications, improving the generalizability of the findings to Group (II) and Group (III) CKD populations. In addition, we determined eGFR using the CKD-EPI equation, which provides a more reliable classification of patients with an eGFR We noticed that self-reported sleep tendency increased as eGFR declined (Group (I), 40%; Group (II), 45.5%; Group (III), 58.3%) (Table 10 ). This was in accordance with Roumelioti and colleagues' study which reported a higher excessive daytime sleepiness among hemodialysis patients than among control subjects (40.6% and 33%, respectively) 19 . Our Study found that mean BMI was highest among group A total of 45 patients (eGFR 60 to 89 ml/min./1.73m2, n 10; eGFR 15 to 59 ml/min./1.73m2, n 11; eGFR <15 ml/min./1.73m2, n 24) were included in this study with matched mean age across the three groups (Group (I), 45.30±9.68; Group (II), 45.27±15.82; Group (III), 45.21±16.66).
(II) patients (32.46±7.81) and lowest among the more severe group (III) patients (23.94±4.45). In consistence with our results, Alramly and colleagues found that predialysis patients with CKD had higher BMI scores than patients receiving dialysis. Loss of association between ESRD and obesity suggest that patients with ESRD are mostly exposed to loss of nutrients through dialysis treatment, anorexia, and anemia (Alramly et al., 2013). Our results revealed statistically significant differences between CKD groups as regards body mass index (BMI) ( Table 11) . Patients with detected sleep apnea and nocturnal hypoxia had BMI of 27.78±5.54 and 27.6±3.46, respectively. Thus, in our opinion, it is possible that altered chemical control of breathing contribute to the pathogenesis of sleep apnea in patients with CKD independently of traditional risk factors for sleep apnea such as obesity. Our study showed that prevalence of sleep apnea increased as kidney function declined (Group (I), 20%; Group (II), 36.4%; Group (III), 37.5%). Furthermore, severity of sleep apnea increased as kidney function declined (Group (I), mean AHI: 5.75±0.35; Group (II), mean AHI: 6±1.38; Group (III), mean AHI: 10.6±7.04). Overall, 15 out of the 45 studied CKD (33.3%) patients had sleep apnea (Mean AHI; 8.71±5.86). Beecroft and colleagues proposed several mechanisms for the increased risk of OSA among patients with CKD. First, the upper airway dimensions in patients with renal failure are prone to narrowing. They reported that the pharyngeal cross-sectional area measured by pharyngometry in end-stage renal disease patients was 12% less than that in the normal renal function control group matched for body mass index (BMI). Such pharyngeal narrowing was considered to occur because of upper airway edema due to systemic fluid overload and upper airway dilator muscle dysfunction due to neuropathy or myopathy associated with chronic uremia. Second, ventilation control is known to be instable in CKD patients. Because chemoreflex responsiveness has been reported to be augmented in patients with end-stage renal disease, possibly because of the accumulation of uremic molecules or metabolic acidosis, this destabilized respiratory control-as explained by a high "loop gain" theory-can contribute to the pathogenesis of OSA. Although these two mechanisms have been established in hemodialysis patients, it is possible that they are also applicable to the nondialysis CKD population 12 .
We also found that prevalence of nocturnal hypoxia which is characteristically associated with sleep apnea was greater among groups (II) and (III) (27.3% and 16.7%, respectively) than in group (I) (10%). Severity of nocturnal hypoxia increased as kidney function declined (Group (I), 13%; Group (II), 13.6±1.22%; Group (III), 16.75±3.30%). Overall, 8 out of the 45 studied CKD patients (17.8%) had nocturnal hypoxia (Mean SaO2 below 90% for ≥12% of the nocturnal monitoring time; 15.1±2.87%). In agreement with our study, Nicholl and colleagues reported a higher prevalence of nocturnal hypoxia among patients with CKD and ESRD than in control subjects (eGFR >60 mL/min/1.73 m 2 , 16%; CKD, 47%; ESRD, 48%; P , .001). Nocturnal hypoxia has been demonstrated to be independently associated with an increased risk for accelerated loss of kidney function (Ahmed et al., 2011) . The chronic hypoxia hypothesis suggests that chronic ischemic damage in the tubulointerstitium of the kidney is the final common pathway for the development of ESRD 11 . If such a process is already under way in patients with CKD, it is possible that ongoing nocturnal hypoxia will amplify the effect and accelerate the decline in kidney function. If so, identification and treatment of nocturnal hypoxia may provide a potential disease-modifying intervention that could delay or halt the progression of CKD to ESRD. Our study revealed that as kidney function declined, Apnea/Hypopnea (AHI) indices increased, oxygen desaturation indices increased, minimal peripheral capillary oxygen saturation values decreased, peripheral capillary No statistically significant differences were detected between studied groups regarding Blood Pressure. oxygen saturation time <90% increased, and snore indices increased (Table 13) . Also, respiratory distress index (RDI) was higher among groups (II) and (III) than in group (I) ( Table 13) . However, only differences between groups as regards respiratory distress events, respiratory distress indices, snore events, and snore indices were statistically significant. These results show that as kidney function declines, several respiratory parameters deteriorate during sleep. In addition, wake events and indices, and sleep stage 1 (%) increased as kidney function deteriorated (Table 14) . Sleep efficiency (%) was highest among group (I) patients and lower among groups (II) and (III), Light sleep (%) was lowest among group (I) patients and higher among groups (II) and (III), and deep sleep (%) was highest among group (I) patients and lower among groups (II) and (III) ( Table 14) . It is clear from the above results that as kidney function declines, sleep efficiency deteriorates, wake indices increase, light sleep (%) increases, and deep sleep (%) decreases.
Previous studies have evaluated the prevalence of sleep apnea in CKD. Markou and colleagues 21 reported a 31.4% prevalence of sleep apnea in a cross-sectional study of 35 patients with CKD, which is similar to our overall 33.3% prevalence. Sim and colleagues 22 reported an increased risk for sleep apnea in CKD patients with eGFR <90 mL/min per 1.73 m2, excluding those with eGFR <15 mL/min per 1.73 m2 and end stage renal disease (ESRD) patients, thus limiting the generalizability of their study. They found a 2.5% prevalence of sleep apnea among their patients. accurately than MDRD, and thus should be the method of choice for estimating GFR. Sagakuchi and colleagues 23 found that Japanese individuals with CKD had a high prevalence (65%) of AHI ≥5 events/h, with one-third of the cohort classified as having moderate (AHI 15 to 29 events/h) or severe (AHI ≥30 events/h) OSA. They used a different modified equation to calculate eGFR for their patients as follows: eGFR = 194 × sCr−1.094 × age−0.287 × 0.739 (if female). In contrast to our study, their work excluded the following: (1) patients who had already undergone renal replacement therapy, (2) those who presented with acute renal failure, and (3) those with severe acute complications such as acute coronary syndrome, acute heart failure, stroke, and systemic infection. The diagnosis of OSA and its severity in their study were measured using a type 3 portable monitor (Morpheus, Teijin Pharma Ltd., Japan). Roumelioti and colleagues 19 reported that OSA is common among individuals with severe CKD (mean eGFR 18.9 ± 7.6 ml/min per 1.73 m2) and those on dialysis therapy compared with a community-based cohort (eGFR 91.8 ± 19.2 ml/min per 1.73 m2). The dialysis group had significantly greater stage 1 ("light sleep") and significantly less stage 2 sleep. Both CKD and hemodialysis groups were more likely to have severe OSA and nocturnal hypoxemia. In agreement with Roumelioti et al., our study revealed increased prevalence and severity of OSA as eGFR declined. Also, in our study, CKD patients with eGFR <15 ml/min./1.73m2 had significantly greater sleep stage 1 ("light sleep") than the other CKD groups and statistically insignificant less sleep stage 2. We found that CKD patients with eGFR <60 mL/min/1.73 m2 had greater light sleep % and less deep sleep % in comparison with the control group (eGFR 60 to 89 ml/min./1.73m2) (Table 14) . Nicholl and colleagues found that the prevalence of sleep apnea increased as eGFR declined (eGFR greater or equal to 60 mL/min/1.73 m2, 27%; CKD, 41%; ESRD, 57%; P 5 .002). Their results matches well with ours (Group (I), 20%; Group (II), 36.4%; Group (III), 37.5%). Fleischmann and colleagues 24 examined 158 patients with CKD who were already suspected of having sleep apnea and, using PSG as an objective measure, were able to document very high rates of sleep apnea (80%-94%). These workers defined sleep apnea differently as the respiratory disturbance index (RDI) > 5 . In this context, Goetting and colleagues claim that the use of the standard method AHI alone for diagnosing OSA leads to underdiagnosis in 30% of cases as compared to the use of the RDI 25 CONCLUSION AND RECOMMENDATIONS Prevalence and severity of sleep apnea in patients with CKD increase as kidney function declines. Almost 18% of patients with CKD experience nocturnal hypoxia that becomes more common and severe as kidney function declines, which may contribute to loss of kidney function. Further studies are required to determine whether treatment of sleep apnea and nocturnal hypoxia improves this clinical outcome in patients with CKD.
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